Managed Access Programs for ABL001, Asciminib

Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia

NCT05384587 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.

NCT06236724 ·Status: RECRUITING ·Phase: PHASE2

Asciminib as Maintenance Treatment After Cellular Therapies for Adults With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

NCT07040982 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1

Asciminib Prospective Non Interventional Study as 3rd Line Therapy or More to Treat Adult Patients With CML- CP in Real World Setting in France

NCT06092879 ·Status: ACTIVE_NOT_RECRUITING

Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia

NCT06773936 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE2

Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma

NCT04402138 ·Status: COMPLETED ·Phase: PHASE2

Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia

NCT06629584 ·Status: RECRUITING ·Phase: PHASE2

Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.

NCT06514534 ·Status: RECRUITING ·Phase: PHASE2

Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)

NCT00079482 ·Status: COMPLETED ·Phase: PHASE2

Frontline Asciminib Combination in Chronic Phase CML

NCT03906292 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid Leukemia

NCT06368414 ·Status: RECRUITING ·Phase: PHASE2

Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL

NCT02475681 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma

NCT02213926 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)

NCT05456191 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL

NCT02081378 ·Status: COMPLETED ·Phase: PHASE1

Efficacy and Safety of Oral AMN107 in Adults With Chronic Myelogenous Leukemia Resistant and/or Intolerant to Imatinib Mesylate Therapy

NCT00264160 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Asciminib Roll-over Study

NCT04877522 ·Status: RECRUITING ·Phase: PHASE4

Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.

NCT03578367 ·Status: COMPLETED ·Phase: PHASE2

Nilotinib, for Patients With CML-CP or CML-AP

NCT04518644 ·Status: NO_LONGER_AVAILABLE

Relatlimab With Nivolumab and 5-Azacytidine for the Treatment of AML

NCT04913922 ·Status: RECRUITING ·Phase: PHASE2

Asciminib Maintenance Therapy Following alloHCT or CAR T to Prevent Relapse in Adults With Ph+ALL

NCT07250087 ·Status: RECRUITING ·Phase: PHASE1

Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)

NCT02477696 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL

NCT03836261 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

NCT06817720 ·Status: RECRUITING ·Phase: PHASE2

Evaluation of a New Anti-cancer Immunotherapy in Adult Acute Myeloid Leukemia Patients With a Suboptimal Clinical Response to Induction Chemotherapy

NCT01051063 ·Status: COMPLETED ·Phase: PHASE1